UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP <150/85 mmHg) reduces/prevents.

Slides:



Advertisements
Similar presentations
BY Dr. Khaled Helmy Al Mahmora Chest Hospital BY Dr. Khaled Helmy Al Mahmora Chest Hospital Treatment Of Hypertension In Diabetes.
Advertisements

Newly diagnosed hypertensive patients with type 2 diabetes (n = 1544) Randomisation Avoid ACE inhibitors/ beta-blockers (n = 390) Tight BP control (n =
ASCOT ASCOT STUDY. ASCOT INTRODUCTION AND AIMS EXISTING KNOWLEDGE BACKGROUND OF ASCOT STUDY DESIGN (TWO ARMS (BPLA,LLA) METHODOLOGY TREATMENT REGIMES.
BLOOD PRESSURE LOWERING. UKPDS design Aim To determine whether intensified blood glucose control, with either sulphonylurea or insulin, reduces the risk.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Valsartan Antihypertensive Long-Term Use Evaluation Results
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Purpose To determine whether metoprolol controlled/extended release
UKPDS Paper 36 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.
UKPDS Paper 35 Slides © University of Oxford Diabetes Trials Unit
UKPDS Paper 81 Slides © University of Oxford Diabetes Trials Unit UKPDS slides are copyright and remain the property of the University of Oxford Diabetes.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
IDC Diabetes Update: Recent Research and Impact on Diabetes Management Type 1 DiabetesType 1 Diabetes –Post DCCT findings--improving glycemic control and.
Blood glucose: is lower better for diabetic patients?
ACUTE STROKE — Hypertension is a common problem in patients with both type 1 and type 2 diabetes but the time course in relation to the duration.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Proteinuria as a surrogate outcome in CKD UKPDS Rudy Bilous Middlesbrough, UK.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Glycemic Control: When the Lower is Not the “Better”?
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Diabetes and the Eye Karen B. Saland, M.D. August 18, 2008.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
ISIS-4: Fourth International Study of Infarct Survival Purpose To assess the separate and combined effects on all-cause mortality of adding early captopril,
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
4S: Scandinavian Simvastatin Survival Study
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
Dr John Cox Diabetes in Primary Care Conference Cork
Diabetes type 2 Landmark Outcomes Trials
HOPE: Heart Outcomes Prevention Evaluation study
The Anglo Scandinavian Cardiac Outcomes Trial
The following slides highlight a presentation at the Hotline Session of the European Society of Cardiology Annual Congress, September 3-7, 2005 in Stockholm,
366 میلیون نفر در جهان مبتلا به دیابت هستند.
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
The following slides highlight a report by Dr
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Presentation transcript:

UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP <150/85 mmHg) reduces/prevents complications and reduces mortality in hypertensive patients with type 2 diabetes Reference UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703 – 13.

UKHDS (UKPDS): UK Hypertension in Diabetes Study - TRIAL DESIGN - Design Randomized, open, controlled trial Patients 1148 hypertensive patients with type 2 diabetes, mean age 56 years, mean BP at entry 160/94 mmHg Follow up and primary endpoint Mean follow up 8.4 years. Primary endpoints morbidity and mortality related to diabetes and all-cause mortality Treatment Tight control of BP with ACE inhibitor (captopril) or beta-blocker (atenolol) aiming for BP <150/85 mmHg, or less tight control aiming for BP <180/105 mmHg. Other agents added if control criteria not met (frusemide, nifedipine, methyldopa and prazosin)

UKHDS (UKPDS): UK Hypertension in Diabetes Study - RESULTS: BP Control and side effects - Mean BP during follow up maintained at significantly lower level in group assigned to tight control (144/82 mmHg) than in group assigned to less tight control (154/87 mmHg) 29% of patients in group assigned to tight control required three or more antihypertensive treatments to maintain BP at target levels No significant difference in cumulative incidence of hypoglycemia in groups assigned to tight (6.1%) and less tight (4.4%) BP control Mean weight gain similar in both groups (1.3 and 2.0 kg, respectively, P=0.13)

UKHDS (UKPDS): UK Hypertension in Diabetes Study - RESULTS: BP Control and side effects - Mean systolic and diastolic BP Years from randomization Blood pressure (mmHg) Less tight control (n=156) Tight control (n=297) UK Prospective Diabetes Study Group. BMJ 1998;317:703–13.

UKHDS (UKPDS): UK Hypertension in Diabetes Study - RESULTS: Morbidity and mortality - Group assigned tight BP control had significant reduction in: —All diabetes-related endpoints combined —Death related to diabetes —Stroke (fatal or non-fatal) —Microvascular end points combined (predominantly due to significantly reduced risk of retinal photocoagulation) —Heart failure Less deterioration of retinopathy and visual acuity in group assigned tight BP control Trends towards reduction in MI, PVD, amputation, fatal/non-fatal renal failure and all-cause mortality were not significant

UKHDS (UKPDS): UK Hypertension in Diabetes Study - RESULTS: : Morbidity and mortality - Tight control (n=758) P Clinical events per 1000 patient years UK Prospective Diabetes Study Group.BMJ 1998;317:703–13. Less tight control (n=390) Relative risk for tight control (95% CI) Clinical end point a Any diabetes-related endpoint (0.62–0.92) b Death related to diabetes (0.49–0.94)0.019 All-cause mortality (0.63–1.08)0.17 c Myocardial infarction (0.59–1.07)0.13 Stroke (fatal and non-fatal) (0.35–0.89)0.013 Peripheral vascular disease (0.19–1.37)0.17 Microvascular disease (0.44–0.89) Retinal photocoagulation (0.39–1.06)0.023 Heart failure (0.20–0.94) a Sudden death, death from hyper/hypoglycemia, fatal/non-fatal MI, angina, heart failure, stroke, renal failure, amputation, vitreous hemorrhage, retinal photocoagulation, blindness in one eye or cataract extraction b Death due to MI, sudden death, stroke, peripheral vascular disease, renal disease, hyper/hypoglycemia c Fatal/non-fatal MI, or sudden death

UKHDS (UKPDS): UK Hypertension in Diabetes Study - RESULTS: : Morbidity and mortality - Tight control (%) P Progression of retinopathy and deterioration in vision UK Prospective Diabetes Study Group. BMJ 1998;317:703–13. Less tight control (%) Relative risk for tight control (95% Cl) Progression of retinopathy by > 2 steps Median 1.5 years Median 4.5 years Median 7.5 years Deterioration in vision by > 3 ETDRS lines a Median 1.5 years Median 4.5 years Median 7.5 years (0.60–1.29) 0.75 (0.55–1.02) 0.66 (0.50–0.89) 0.79 (0.39–1.62) 0.83 (0.44–1.59) 0.53 (0.30–0.93) a ETDRS = early treatment of diabetic retinopathy study

UKHDS (UKPDS): UK Hypertension in Diabetes Study - SUMMARY - In hypertensive patients with type 2 diabetes, long-term tight BP control aiming to keep BP <150/85 mmHg by use of an ACE inhibitor or beta-blocker (plus additional anti-hypertensive treatment if necessary): Achieved mean BP of 144/82 mmHg Reduced risk of diabetic complications and death related to diabetes Reduced risk of progression of diabetic retinopathy and deterioration in visual acuity